Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2014

Supporting Information

Palladium-Catalyzed Synthesis of Isoindoloquinazolinones via Dicarbonylation of 1,2-Dibromoarenes

Jianbin Chen, Helfried Neumann, Matthias Beller and Xiao-Feng Wu*

Leibniz-Institut für Katalyse an der Universität Rostock e.V. Albert-Einstein-Str. 29a, 18059 Rostock, Germany Email: xiao-feng.wu@catalysis.de

Table of Contents

1. General Considerations	S2
2. Materials	S2
3. General Procedure for the Synthesis of Isoindoloquinazolinone	S2
4. Characterization Data of Products	S3-S5
5. References	85
6. Copies of the Products ¹ H NMR and ¹³ C NMR	S6-S12

1. General Considerations

Nuclear Magnetic Resonance spectra were recorded on Bruker Avance 300 and Bruker ARX 400 spectrometers. All ¹H NMR experiments were reported in δ units, parts per million (ppm), and were measured relative to residual chloroform (7.26 ppm) or DMSO (2.5 ppm) in the deuterated solvent. All ¹³C NMR spectra were reported in ppm relative to deuterochloroform (77.0 ppm) or DMSO-*d*₆ (39.5 ppm) and all were obtained with ¹H decoupling. All coupling constants *J*, were reported in Hz. The following abbreviations were used to describe peak splitting patterns when appropriate: s = singlet, d = doublet, t = triplet, dd = doublet of doublet, m = multiplet and br s = broad singlet. All measurements were carried out at room temperature unless otherwise stated. Electron impact (EI) mass spectra were recorded on AMD 402 mass spectrometer (70 eV). High resolution mass spectra (HRMS) were recorded on Agilent 6210. The data were given as mass units per charge (m/z). Gas chromatography analysis was performed on an Agilent HP-5890 instrument with a FID detector and HP-5 capillary column (polydimethylsiloxane with 5 % phenyl groups, 30 m, 0.32 mm i.d., 0.25 µm film thickness) using argon as carrier gas. The products were isolated from the reaction mixture by column chromatography on silica gel 60, 0.063-0.2 mm, 70-230 mesh (Merck).

2. Materials

DMA (anhydrous, 99.8 %) was purchased from Sigma-Aldrich and degassed with Argon before used. All Chemicals were commercial available and were used without further purification unless otherwised noted.

3. General Procedure for the Synthesis of Isoindoloquinazolinone

The reaction was carried out in a Parr Instruments 4560 series 300 ml autoclave containing an alloy plate with wells for five 12 ml Wheaton vials. $Pd(OAc)_2$ (2 mol %), $BuPAd_2$ (6 mol %) and a stirring bar were placed in each vials, which were then capped with a septum equipped a inlet needle and flushed with argon 3 times. Then, Et_3N (3.0 equiv.), *o*-dibromobenzene (0.5 mmol, 1 equiv.) and DMA (2 mL) were injected *via* syringe under argon. The vial (or several vials) was placed in an autoclave under argon atmosphere. After flushing the autoclave three times with CO, a pressure of 10 bars of CO was adjusted at ambient temperature. The reaction was performed for 16h at 120 °C. After the reaction completed, the autoclave was cooled down with ice water to room temperature and the pressure was released carefully. The solution was extracted 3-5 times with ethyl acetate form saturated brine and dried with Mg_2SO_4 . After evaporation of the organic solvent the residue was adsorbed on silica gel and the crude product was purified by column chromatography using EA/pentane (1:10-1:2) as eluent.

4. Characterization Data of Products

Isoindolo[1,2-b]quinazolin-12(10H)-one^[1]



¹**H NMR (300 MHz, CDCl₃)** δ 7.96 – 7.88 (m, 1H), 7.82 – 7.72 (m, 1H), 7.65 – 7.47 (m, 2H), 7.35 (dd, *J* = 7.8, 1.4 Hz, 1H), 7.25 – 7.15 (m, 1H), 7.11 (td, *J* = 7.4, 1.4 Hz, 1H), 7.07 – 7.00 (m, 1H), 4.83 (s, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 166.8, 148.8, 140.2, 134.4, 132.8, 132.0, 130.4, 128.7, 128.0, 127.6, 126,8, 123.0, 122.1, 121.2, 40.6.

GC-MS (EI, 70eV): m/z [M⁺-H] (%) 233 (100), 205 (9), 102 (10), 77 (8).

HRMS (EI) [M⁺-H]: calcd. For C₁₅H₉ON₂: 233.07094; found: 233.07079.

HRMS (ESI): calcd. for [M+H]⁺, C₁₅H₁₁ON₂: 235.08659; found: 235.08659.

2,3-Dimethylisoindolo[1,2-b]quinazolin-12(10H)-one



¹**H NMR (300 MHz, CDCl₃)** δ 7.67 (s, 1H), 7.51 (s, 1H), 7.33 (dd, *J* = 7.8, 1.4 Hz, 1H), 7.25 – 7.15 (m, 1H), 7.10 (td, *J* = 7.4, 1.4 Hz, 1H), 7.03 (dd, *J* = 7.6, 1.6 Hz, 1H), 4.79 (s, 2H), 2.30 (s, 3H), 2.29 (s, 3H).

¹³C NMR (**75** MHz, CDCl₃) δ 167.2, 149.2, 142.5, 141.6, 140.4, 132.3, 128.6, 128.3, 127.8, 127.3, 126.8, 123.9, 123.0, 121.3, 40.5, 20.4.

HRMS (ESI): calcd. for [M+H]⁺, C₁₇H₁₅ON₂: 263.11789; found: 263.11777.

[1,3]Dioxolo[4',5':5,6]isoindolo[1,2-b]quinazolin-12(10H)-one



¹H NMR (300 MHz, CDCl₃) δ 7.52 – 7.38 (m, 2H), 7.36 – 7.28 (m, 1H), 7.26 – 7.13 (m, 3H), 6.15 (s, 2H), 4.93 (s, 2H). ¹³C NMR (75 MHz, CDCl₃) δ 166.5, 152.1, 151.4, 148.8, 140.4, 130.2, 128.7, 128.0, 127.5, 126.9, 125.7, 121.3, 103.3, 102.6, 102.6, 40.7.

GC-MS (EI, 70 eV): m/z (%) = 277 ([M-H]⁺, 100), 138 (9).

HRMS (ESI): calcd. for [M+H]⁺, C₁₆H₁₁O₃N₂: 279.07642; found: 279.07665.

2,3-Dimethoxyisoindolo[1,2-b]quinazolin-12(10H)-one



¹H NMR (300 MHz, CDCl₃) δ 7.50 – 7.36 (m, 2H), 7.35 – 7.23 (m, 2H), 7.17 (dd, *J* =7.4, 1.6 Hz, 2H), 4.87 (s, 2H), 3.03 (s, 3H), 2.94 (s, 3H).
¹³C NMR (75 MHz, CDCl₃) δ 170.4, 166.7, 152.9, 152.3, 148.8, 140.1, 128.3, 127.6, 127.4, 127.1, 126.6, 123.2, 121.1, 104.5, 103.8, 56.2, 56.1, 40.3.
GC-MS (EI, 70 eV): m/z (%) = 293 ([M-H]⁺, 100), 277 (18).

HRMS (ESI): calcd. for $[M+H]^+$, $C_{17}H_{15}O_3N_2$: 295.10772; found: 295.10801.

3-Methylpyrido[3',2':3,4]pyrrolo[2,1-*b*]quinazolin-12(10*H*)-one 3-Methylpyrido[2',3':3,4]pyrrolo[2,1-*b*]quinazolin-5(7*H*)-one



¹**H** NMR (300 MHz, CDCl₃) selected signal for the main products. δ 8.64 – 8.60 (m, 1H), 8.02 – 7.96 (m, 1H), 7.31 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.12 (td, *J* = 7.3, 1.9 Hz, 2H), 7.05 (d, *J* = 1.6 Hz, 1H), 4.86 (s, 2H), 2.81 – 1.94 (m, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 164.6, 164. 6, 154.8, 154.3, 151.0, 147.1, 147.0, 146.1, 139.8, 139.6, 137.1, 136.5, 130.9, 129.9, 129.3, 129.0, 128.7, 128.7, 128.1, 128.0, 127.9, 126.8, 126.6, 125.2, 121.4, 121.0, 40.5, 40.4, 19.0.

GC-MS (EI, 70 eV): m/z (%) = 248 ([M-H]⁺, 100), 220 (9).

HRMS (ESI): calcd. for [M+H]⁺, C₁₅H₁₂ON₃: 250.09749; found: 250.0975. calcd. for [M+Na]⁺, C₁₅H₁₁ON₃Na: 272.07943; found: 272.07934.

Benzo[4',5']thieno[3',2':3,4]pyrrolo[2,1-*b*]quinazolin-6(8*H*)-one Benzo[4',5']thieno[2',3':3,4]pyrrolo[2,1-*b*]quinazolin-13(11*H*)-one



¹H NMR (300 MHz, CDCl₃) selected signal for the main products δ 8.30 (dt, J = 8.1, 1.0 Hz, 1H), 7.87 – 7.74 (m, 2H), 7.51 – 7.33 (m, 2H), 7.30 – 7.00 (m, 3H), 4.81 (s, 2H).

¹³C NMR (75 MHz, CDCl₃) selected signal for the main products δ 162.5, 146.6, 145.9, 140.2, 140.2, 138.2, 131.0, 128.9, 128.8, 128.7, 127.9, 127.2, 126.9, 126.2, 124.4, 123.9, 121.5.
GC-MS (EI, 70 eV): m/z (%) = 289 ([M-H]⁺, 100), 261 (9), 130 (11).
HRMS (ESI): calcd. for [M+H]⁺, C₁₇H₁₁SN₂: 291.05866; found: 291.05853.

2-Methylisoindolo[1,2-b]quinazolin-12(10H)-one

3-Methylisoindolo[1,2-b]quinazolin-12(10H)-one



¹H NMR (300 MHz, CDCl₃) δ 7.88 (d, J = 7.7 Hz, 1H), 7.81 (s, 1H), 7.73 (d, J = 7.7 Hz, 1H), 7.65 (d, J = 1.5 Hz, 1H), 7.52 – 7.39 (m, 4H), 7.36 – 7.24 (m, 2H), 7.19 (tt, J = 7.3, 1.4 Hz, 2H), 7.12 (dd, J = 7.3, 1.8 Hz, 2H), 4.91 (s, 4H), 2.49-2.48 (m, 6H).
¹³C NMR (75 MHz, CDCl₃) δ 167.0, 166.9, 149.1, 149.0, 143.9, 143.0, 140.3, 134.7, 133.7, 132.8, 131.8, 130.7, 130.1, 128.7, 128.0, 127.9, 127.9, 127.5, 127.4, 126.8, 126.4, 125.4, 123.5, 122.9, 122.6, 122.0, 121.3, 121.2, 40.6, 21.9, 21.9.
GC-MS (EI, 70 eV): m/z (%) = 247 ([M-H]+, 100), 219 (6).

HRMS (ESI): calcd. for [M+H]+, C16H13ON2: 249.10224; found: 249.10266.

5. References

[1] M.-C. Tseng, P.-Y. Lai, L. Shi, H.-Y. Li, M.-J. Tseng, Y.-H. Chu Tetrahedron 2014, 70, 2629-2633.













